Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Gynecology

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 58 articles:
HTML format



Single Articles


    October 2025
  1. BARAT S, Ahmadi N, Wijayawardana R, Liauw W, et al
    Survival Outcomes Post-secondary Cytoreduction in Peritoneal Metastatic Cases from Ovarian Cancer: A Single Institute Study.
    Anticancer Res. 2025;45:4281-4293.
    PubMed     Abstract available


  2. HIKINO K, Komatsu H, Kazuki Y, Kazuki K, et al
    Matrix Metalloproteinase-1 as an Independent Prognostic Biomarker in Epithelial Ovarian Carcinoma.
    Anticancer Res. 2025;45:4473-4481.
    PubMed     Abstract available


    September 2025
  3. PARK SJ, Koh JW, Lee TB, Han SI, et al
    Biological Role of Replication Factor C Subunit 4 in Cervical Cancer Cell Progression.
    Anticancer Res. 2025;45:3701-3710.
    PubMed     Abstract available


  4. FURUKAWA S, Soeda S, Endo H, Yoshimoto Y, et al
    Multidisciplinary Therapy of Uterine Ewing's Sarcoma With the Preservation of Uterus and Ovarian Function by Laparoscopy: A Case Report and Literature Review.
    Anticancer Res. 2025;45:4027-4035.
    PubMed     Abstract available


    August 2025
  5. MUKOHYAMA J, Saito I, Mochizuki S, Ota Y, et al
    Endometrial Cancer Metastatic to the Sigmoid Colon and Pelvic Retroperitoneal Space: A Case Report.
    Anticancer Res. 2025;45:3567-3573.
    PubMed     Abstract available


  6. AKAZAWA M, Hashimoto K, Nagano H
    Development and External Validation of Machine Learning-based Models for Predicting Survival Outcomes in Endometrial Cancer: A Population-based Study.
    Anticancer Res. 2025;45:3543-3551.
    PubMed     Abstract available


  7. KIYOSHIMA C, Urushiyama D, Yoshikawa K, Ishida K, et al
    microRNA in Chorioamnionitis: Emerging Biomarkers for Early Diagnosis.
    Anticancer Res. 2025;45:3587-3594.
    PubMed     Abstract available


    July 2025
  8. LI M, Yan J, Wei S, Zhao S, et al
    Macranthoside B Enhances Paclitaxel-induced Human Cervical Cancer Cell Apoptosis Through ROS-JNK Pathway.
    Anticancer Res. 2025;45:2859-2870.
    PubMed     Abstract available


  9. MICHA JP, Bohart RD, Gorman JP, Goldstein BH, et al
    Immunotherapy and Chemotherapy for Advanced or Recurrent Endometrial Carcinoma.
    Anticancer Res. 2025;45:2711-2717.
    PubMed     Abstract available


  10. CRISPO A, Luongo A, Nocerino D, Cascella M, et al
    Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study.
    Anticancer Res. 2025;45:3149-3164.
    PubMed     Abstract available


    May 2025
  11. WEHBE S, Gallwas J, Grundker C
    Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Reduces Aggressiveness of Cervical Carcinoma Cells.
    Anticancer Res. 2025;45:1793-1805.
    PubMed     Abstract available


  12. BAL J, Fulawka L, Gabrys M, Murawski M, et al
    Potential Role of PTEN and AKT/PKB Proteins in the Pathogenesis of Ovarian Mature Teratomas.
    Anticancer Res. 2025;45:1843-1851.
    PubMed     Abstract available


  13. SIMONETTI E, Pistolesi S, Ferrari A, Della Rosa M, et al
    Role of Stromal CD25+/CD8+ Lymphocyte Ratio in Patients With Grade 2-3 Cervical Intraepithelial Neoplasia (CIN 2-3): A Retrospective Single-center Study.
    Anticancer Res. 2025;45:2041-2050.
    PubMed     Abstract available


  14. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
    Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
    Anticancer Res. 2025;45:2071-2078.
    PubMed     Abstract available


    April 2025
  15. DAMPALI R, Nikolettos K, Psilopatis I, Kostaki EG, et al
    The Impact of Body Mass Index on Sentinel Lymph Node Identification in Endometrial Cancer.
    Anticancer Res. 2025;45:1575-1581.
    PubMed     Abstract available


    March 2025
  16. WU YC, Ku MH, Huang WL, Dias L, et al
    NEAT1 in Ovarian Cancer: A Key Regulator of Tumor Progression, Follicular Fluid Dynamics, and Therapeutic Resistance.
    Anticancer Res. 2025;45:825-842.
    PubMed     Abstract available


  17. AHMADU T, Olawade DB, Teke J, Bachour ME, et al
    Diagnosis and Treatment of Gestational Non-Epithelial Ovarian Cancer: A Systematic Review.
    Anticancer Res. 2025;45:843-853.
    PubMed     Abstract available


  18. KOH JW, Park SJ
    Knockdown of RFC2 Prevents the Proliferation, Migration and Invasion of Cervical Cancer Cells.
    Anticancer Res. 2025;45:989-1000.
    PubMed     Abstract available


    February 2025
  19. STUEBS FA, Dietl AK, Schulmeyer CE, Behrens AS, et al
    Prognostic Significance of the Detection of Human Papilloma Virus L1 Protein in Smears of Cervical Intraepithelial Neoplasia Grade 3 in Pregnant Women.
    Anticancer Res. 2025;45:677-683.
    PubMed     Abstract available


  20. SANTANA BN, Arencibia O, Babin G, Tommasetti E, et al
    Use of Indocyanine Green Fluorescence Angiography to Assess Bowel Anastomosis in Ovarian Cancer Surgery.
    Anticancer Res. 2025;45:661-666.
    PubMed     Abstract available


  21. SHIEH PC, Shih HY, Chuang CL, Tsai CW, et al
    Association of Matrix Metalloproteinase-1 Promoter Genotypes With Endometriosis Risk.
    Anticancer Res. 2025;45:465-471.
    PubMed     Abstract available


    January 2025
  22. TALIJANOVIC M, Lopacinska-Jorgensen J, Hogdall EV
    Gene Expression Profiles in Ovarian Cancer Tissues as a Potential Tool to Predict Platinum-based Chemotherapy Resistance.
    Anticancer Res. 2025;45:11-26.
    PubMed     Abstract available


  23. KARSTENSEN S, Kaiser K, Poulsen TS, Jochumsen K, et al
    Ovarian Adult Granulosa Cell Tumors: A Scoping Review of DNA Alterations and Their Known Significance.
    Anticancer Res. 2025;45:1-10.
    PubMed     Abstract available


  24. LINDQVIST PG, Gissler M
    Improved Vitamin D Status Is Associated With Lower Incidence of Stillbirth.
    Anticancer Res. 2025;45:243-250.
    PubMed     Abstract available


    December 2024
  25. KONTOMANOLIS E, Koutras A, Mitrakas AG, Trypsianis G, et al
    Tissue Expression and Plasma Soluble PD-L1 Levels in Patients With Endometrial Cancer.
    Anticancer Res. 2024;44:5525-5530.
    PubMed     Abstract available


  26. ULKER EB, Aktas EC, Seyhan MF, Isbir T, et al
    Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells.
    Anticancer Res. 2024;44:5351-5359.
    PubMed     Abstract available


  27. CHO Y, Kim HS
    Immunohistochemical Expression and Significance of Preferentially Expressed Antigen in Melanoma (PRAME) in Gynecological Tumors: A Single-institution Retrospective Analysis.
    Anticancer Res. 2024;44:5515-5524.
    PubMed     Abstract available


    November 2024
  28. LENZ C, Gesemann L, Al-Baldawi Y, Pusken M, et al
    Accuracy of Preoperative Magnet Resonance Imaging to Predict Pathologic T-Stage in Patients With Cervical Cancer.
    Anticancer Res. 2024;44:5081-5085.
    PubMed     Abstract available


  29. NA JM, Kim HS
    Comprehensive Clinicopathological and Immunohistochemical Analysis of Human Papillomavirus-independent Squamous Cell Carcinoma and Adenosquamous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2024;44:4969-4981.
    PubMed     Abstract available


  30. COCCHI S, Lopacinska-Jorgensen J, Hogdall EV
    Potential Transcriptomic Biomarkers for Predicting Platinum-based Chemotherapy Resistance in Patients With High-grade Serous Ovarian Cancer.
    Anticancer Res. 2024;44:4691-4707.
    PubMed     Abstract available


  31. LEE HM, Cho HJ, Lee YM, Kim HJ, et al
    Fostamatinib Inhibits the Proliferation of Ovarian Cancer Cells Through Apoptosis Induction.
    Anticancer Res. 2024;44:4895-4903.
    PubMed     Abstract available


  32. SIN J, Kiosea M, Mahdavi K, Akbarpour F, et al
    Investigation of the Efficacy of Nowarta110 in the Treatment of HPV-16 and HPV-18 Oncogenically-transformed Human Cells and Cancer-implanted Animal Models.
    Anticancer Res. 2024;44:4723-4728.
    PubMed     Abstract available


  33. LEE J, Chi SA, Choi S, Kim HS, et al
    Invasive Stratified Mucin-producing Carcinoma of the Uterine Cervix: Comparison of Its Clinicopathological Characteristics and Programmed Death-ligand 1 Expression Status With Those of Other Endocervical Adenocarcinomas.
    Anticancer Res. 2024;44:5007-5022.
    PubMed     Abstract available


    October 2024
  34. SANTANA BN, Guyon F, Arencibia O, Babin G, et al
    Factors Limiting Ostomy Reversal After Cytoreductive Surgery for Ovarian Cancer: A Retrospective Study.
    Anticancer Res. 2024;44:4413-4418.
    PubMed     Abstract available


  35. LEE J, Heo K
    Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth.
    Anticancer Res. 2024;44:4301-4307.
    PubMed     Abstract available


  36. HA H, Ryu JY, Yoon S, Cho YJ, et al
    Anticancer Effects of BAF312 (Siponimod) in Epithelial Ovarian Cancer.
    Anticancer Res. 2024;44:4273-4282.
    PubMed     Abstract available


    September 2024
  37. SMOLARZ B, Lukasiewicz H, Samulak D, Kolacinski R, et al
    Hypoxia-induced Factor-1alpha and its Role in Endometrial Cancer.
    Anticancer Res. 2024;44:3697-3712.
    PubMed     Abstract available


    August 2024
  38. KYRIAZOGLOU A, Papachristou DJ, Moutafi M, Papakosta A, et al
    Implications of the Hippo Pathway Dysregulation in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:3331-3336.
    PubMed     Abstract available


  39. HIRAKAWA T, Yotsumoto F, Imi S, Ito N, et al
    Adipose-derived Mesenchymal Stem Cell Transplantation Improves Ovarian Function and Oocyte Quality in Aged Mice.
    Anticancer Res. 2024;44:3577-3586.
    PubMed     Abstract available


    July 2024
  40. LI Q, Guan T, Mao J, King BP, et al
    Mast Cell-related Prognosis Signature Characterizes Immune Landscape and Predicts Prognosis of Ovarian Cancer.
    Anticancer Res. 2024;44:2775-2786.
    PubMed     Abstract available


  41. CHIEN HJ, Wang YC, Chang WS, Hsieh YH, et al
    Contribution of Matrix Metalloproteinase-7 Genotypes to Endometriosis Risk in Taiwan.
    Anticancer Res. 2024;44:3051-3058.
    PubMed     Abstract available


  42. CHOI EY, Han EJ, Jeon SJ, Lee SW, et al
    Kaempferol Inhibits Cervical Cancer Cells by Inducing Apoptosis and Autophagy via Inactivation of the PI3K/AKT/mTOR Signaling Pathway.
    Anticancer Res. 2024;44:2961-2972.
    PubMed     Abstract available


  43. MAFUNE S, Someya M, Hasegawa T, Tsuchiya T, et al
    Analysis of Treatment Response With Proteins Related to Tumor Immunity in Postoperative Irradiated Cervical Cancer Patients.
    Anticancer Res. 2024;44:3077-3086.
    PubMed     Abstract available


  44. ZHANG Y, Niu X, Wang Y, Bao S, et al
    SIRT4 Has an Anti-Cancer Role in Cervical Cancer by Inhibiting Glutamine Metabolism via the MEK/ERK/C-Myc Axis.
    Anticancer Res. 2024;44:2861-2870.
    PubMed     Abstract available


    June 2024
  45. LEONHARDI J, Horn LC, Aktas B, Denecke T, et al
    MRI Texture Analysis of Inguinal Lymph Node Metastasis in Vulvar Cancer - Associations With Histopathology.
    Anticancer Res. 2024;44:2709-2716.
    PubMed     Abstract available


  46. MORGENSTERN B, Thangarajah F, Schmidt M, Lenz C, et al
    Clinical Impact of Pelvic Sentinel Lymph Node Biopsy for Vulvar Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2621-2626.
    PubMed     Abstract available


  47. KITSOS-KALYVIANAKIS K, Pitsikakis K, Mamalis ME, Kalampokis E, et al
    Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence.
    Anticancer Res. 2024;44:2645-2652.
    PubMed     Abstract available


    May 2024
  48. YAMAOKA Y, Tamura S, Yamanoi K, Taki M, et al
    Clinical Significance of Serum SCC Levels Before Treatment for Locally Advanced Cervical Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2009-2019.
    PubMed     Abstract available


  49. JUNG BC, Woo SH, Kim SH, Kim YS, et al
    Parkin Enhances Gefitinib-induced Anoikis in HeLa Cervical Cancer Cells.
    Anticancer Res. 2024;44:1853-1862.
    PubMed     Abstract available


  50. WILLSON CM, Lequio M, Zhu Z, Wakefield MR, et al
    The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells.
    Anticancer Res. 2024;44:1807-1815.
    PubMed     Abstract available


  51. KUM SJ, Jung YY, Kim HS
    Comparison of Clinicopathological and Prognostic Characteristics Between Minimal Deviation Adenocarcinoma and Gastric-type Endocervical Adenocarcinoma.
    Anticancer Res. 2024;44:2193-2204.
    PubMed     Abstract available


  52. MOREA A, Saravi S, Sisu C, Hall M, et al
    Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model.
    Anticancer Res. 2024;44:1817-1827.
    PubMed     Abstract available


    April 2024
  53. XU X, Wang Q, Shen L, Shen Y, et al
    Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity via Suppressing NOTCH2 Expression and Stemness.
    Anticancer Res. 2024;44:1399-1407.
    PubMed     Abstract available


  54. TSENG CC, Ku MH, Wu YC, Huang WL, et al
    Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer.
    Anticancer Res. 2024;44:1353-1364.
    PubMed     Abstract available


  55. CHU J, Lee SH, DO SI, Kim HS, et al
    Clinicopathological Significance of Nucleosome Remodeling and Deacetylase Complex Expression in Endometrial Carcinoma.
    Anticancer Res. 2024;44:1739-1750.
    PubMed     Abstract available


  56. AOSHIKA T, Noda SE, Abe T, Kumazaki YU, et al
    Results of Definitive (Chemo)radiotherapy Using Computed Tomography-based Brachytherapy for Cervical Cancer.
    Anticancer Res. 2024;44:1583-1589.
    PubMed     Abstract available


  57. WANG X, Li C, Lou L, Zhu H, et al
    Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
    Anticancer Res. 2024;44:1465-1473.
    PubMed     Abstract available


    March 2024
  58. KIM JS, Shin MJ, Lee SY, Choi SM, et al
    BBT-877, a Novel Autotaxin Inhibitor, Abrogates Drug Resistance in Epithelial Ovarian Cancer Stem Cells.
    Anticancer Res. 2024;44:1131-1142.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.